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See Article, pages 688–694Chronic co-infection with hepatitis B virus (HBV)
and hepatitis C virus (HCV) is generally associated with
severe forms of liver disease that may have a serious
prognosis and high risk of death mostly due to their pro-
pensity to progress toward cirrhosis and to develop
hepatocellular carcinoma [1–11]. In spite of the consid-
erable clinical impact, many aspects concerning this dual
infection have been insuﬃciently explored so far. In par-
ticular, very little is known from the therapeutic point of
view, and guidelines for its treatment have not been
drawn up to date. This paucity is mainly due to the fact
that most studies on the natural and post-therapeutic
course of chronic hepatitis C foresee, among the main
exclusion criteria, the coexisting presence of the HBV
‘‘s” antigen (HBsAg). Vice versa, antibody to HCV
(anti-HCV) positive subjects are excluded from the stud-
ies on HBV-related liver disease.
Nevertheless, the few available studies in this ﬁeld
acknowledge that this particular form of chronic viral
hepatitis is particularly diﬃcult to cure [12–16]. Several
reports suggested an interplay between HBV and HCV
in the case of co-infection (reviewed in [4] and [17]), with
a prevalent role of HCV suppressing the HBV activity
through the core protein that is able to inhibit HBV rep-
lication, as ‘‘in vitro” studies showed [18–21]. In this
context, some anecdotal reports concerning co-infected
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the previously suppressed HBV when a favourable
response to therapy was achieved in terms of serum
HCV RNA disappearance [15,22]. In other words, the
cure of the HCV infection in these cases would produce
the loss of the inhibitory eﬀect exerted by HCV on HBV,
thus allowing its reactivation. In this issue of the Jour-
nal, Potthoﬀ and co-workers report the results of their
pilot study on the eﬀect of pegylated interferon (PEG-
IFN) plus ribavirin therapy in a group of HBV/HCV
co-infected patients with chronic liver disease [23]. They
found an excellent response concerning the HCV infec-
tion, with a sustained virological response (documented
by the absence of viral RNA 6 months after the end of
treatment) in 14 out of the 15 patients who completed
the study. Thus, PEG-IFN plus ribavirin treatment
maintains its therapeutic eﬃcacy on HCV in cases with
HBV co-infection. Concerning the behaviour of HBV,
two patients with detectable HBV DNA at baseline
became HBV DNA negative at the end of post-treat-
ment follow-up, whereas in four individuals the viral
DNA, which was negative at baseline, became detect-
able 6 months after stopping therapy when they tested
negative for HCV RNA. These results led the authors
to consider the former two cases as good responders
to the PEG-IFN therapy for both the viruses, whereas
in the latter four cases the cure of the HCV infection
would have produced the loss of the suppressive eﬀect
of HCV with consequent HBV reactivation.
A major question arises from this study: is it suﬃcient
to test HBV DNA just once before starting antiviral
therapy to distinguish between productive and
suppressed HBV infection in this category of patients?ed by Elsevier B.V. Open access under CC BY-NC-ND license.
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antibody to HBV ‘‘e” antigen (anti-HBe) positive hepa-
titis B is often characterized by phases of low levels of
HBV replication interspersed with episodes of viral
reactivation [24–27], and actually all but one of the 19
cases initially included in the study by Potthoﬀ et al.
were anti-HBe positive.
In a recent Italian multicenter study that examined the
largest series of HBsAg and anti-HCV positive patients
longitudinally analysed so far, it was shown that a wide
and complex spectrum of virological proﬁles may occur
in cases of co-infection [28]. This study enrolled 133
untreated HBsAg/anti-HCV positive patients who were
followed up for one year with bimonthly evaluation of
HBV/HCV viremia levels and liver biochemistry. One
third of these patients presented alternate phases of inhi-
bition and recurrence of the activity of one or both the
viruses, as revealed by broad changes over time of the
amount of circulating HBV DNA or, less frequently,
HCV RNA. Moreover, the longitudinal proﬁle of each
virus in all the cases with ﬂuctuating virological patterns
appeared to be totally independent of the viremia levels
of the other virus. Finally, a similarly dynamic virologi-
cal proﬁle was observed in a subgroup of individuals with
triple viral hepatitis infection (HBV, HCV and Delta
hepatitis virus).
A subsequent study investigated the behaviour of
apparently inactive HBV infection in patients under
treatment for a concurrent HCV infection [29]: the inac-
tive HBV status was maintained independently of the
HCV response to therapy in all but two non-responder
cases with persistently high HCV viremia levels. These
two patients showed HBV DNA ﬂares during the antivi-
ral treatment, indicating a status of productive HBV
infection with ﬂuctuating virological proﬁle, thus sug-
gesting that the HBV behaviour may be independent
of the HCV activity during anti-HCV therapy in individ-
uals with combined infection.
Therefore, a single point evaluation of viral DNA lev-
els cannot allow any reliable conclusion about the status
of activity of theHBV in cases with single infection as well
as in patients with HCV co-infection. Thus, the deﬁnition
of the behaviour of each virus implied in the dual infection
should be longitudinally evaluated before starting any
antiviral treatment in order to deﬁne whether one or both
the virus(es) is (are) responsible for the liver injury in each
individual case and, consequently, to choose the best ther-
apeutic option that also has to take into account the pos-
sible use of anti-HBV nucleos(t)ide analogues.Moreover,
once therapy is started, the virological follow-up should
be continued in order to recognize possible reactivation
of a previously quiescent infection and to adapt the ther-
apy to the new virological scenario.
In conclusion, the study by Potthoﬀ and co-workers
clearly conﬁrms that international guidelines for the
treatment of HBV/HCV co-infection are needed. Forthis purpose, larger therapeutic trials should urgently
be designed and performed, and these trials must take
into account the complex and frequently unpredictable
virological proﬁle of this clinically important – but until
now understudied – category of patients.References
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